A healthcare policy change passed in France is likely to see the country quickly targeted by medicinal cannabis companies with Little Green Pharma (ASX: LGP) quick to confirm their plans to increase product distribution to the country thanks to newly favourable healthcare legislation. The recent amendment to the Projet de loi de financement de la
Read More
Over the years, the Australian cannabis market has consistently posted revenue growth and is expected to be valued at $1.1 billion by 2028. Both Aussies and Europeans are big consumers of cannabis, making them attractive markets for medical cannabis companies like Little Green Pharma (ASX: LGP). Little Green Pharma posted a 37% revenue spike to
Read More
Advancing their research and development for medicinal cannabis applications, Little Green Pharma (ASX: LGP) has joined the global movement for use of psychedelics for treatment of mental illness having secured regulatory approval to supply psilocybin. The approvals come in the form of a Schedule 9 licence granted by the WA Department of Health which enables
Read More
Members of private health insurer Health Insurance Fund (HIF) will be given priority access to Little Green Pharma (ASX: LGP) and their research into medicinal cannabis with the two commencing a strategic partnership focused on improving patient quality of life. Under the partnership, HIF members will be given priority participation in Little Green Pharma product
Read More
Australian medicinal cannabis and healthcare company Little Green Pharma (ASX: LGP) has this morning announced a key purchase agreement with Berlin-based DEMECAN for the sale and export of up to 1000kg of dried cannabis flower or 48,000 units of medicinal cannabis per annum. The agreement makes LGP one of the first few companies to export
Read More